Intervention
Ranolazine
ClinicalTrials.gov intervention label
Explore related research
Search across original and mapped recordsSearch results distinguish clinical terminology from original registry names. Shared trial participation does not imply treatment or approval.
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 22 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
22 shownFeasibility Trial for a Right Ventricular Failure Platform TrialNCT06570473 · 2025-07-15
RECRUITINGDoes Ranolazine Decrease Biomarkers of Myocardial Damage in DiabeticsNCT02611596 · 2016-11-01
WITHDRAWNTargeting Right Ventricle in Pulmonary Hypertension GileadNCT02829034 · 2016-07-01
COMPLETEDA Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor RanolazineNCT01992016 · 2014-04-07
COMPLETEDTargeting the Right Ventricle in Pulmonary HypertensionNCT01839110 · 2013-07-01
COMPLETEDThe Use of Ranolazine for Atrial Fibrillation and Diastolic Heart FailureNCT01887353 · 2013-06-01
TERMINATEDEffects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CADNCT01754259 · 2013-04-01
COMPLETEDA Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.NCT01843127 · 2013-04-01
COMPLETEDA Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin AloneNCT01555164 · 2012-06-01
COMPLETEDSingle Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mgNCT01546558 · 2012-02-01
COMPLETEDSingle Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With RanolazineNCT01546597 · 2012-02-01
COMPLETEDRanolazine When Added to Glimepiride in Subjects With Type 2 Diabetes MellitusNCT01494987 · 2012-01-01
COMPLETEDRanolazine Monotherapy in Subjects With Type 2 Diabetes MellitusNCT01472185 · 2011-11-01
COMPLETEDRanolazine Implantable Cardioverter-Defibrillator TrialNCT01215253 · 2011-09-01
COMPLETEDType 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable AnginaNCT01425359 · 2011-09-01
COMPLETEDA Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial HypertensionNCT01757808 · 2011-08-01
COMPLETEDStudy of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular DysfunctionNCT02133352 · 2011-07-01
COMPLETEDA Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)NCT01334203 · 2011-05-01
WITHDRAWNThe Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection FractionNCT01505179 · 2011-02-01
COMPLETEDExploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic TherapyNCT01163721 · 2010-06-01
COMPLETEDRanolazine and Pulmonary HypertensionNCT01174173 · 2010-06-01
COMPLETEDRanolazine in Diastolic Heart FailureNCT01163734 · 2010-04-01
COMPLETEDCommon conditions
Type 2 Diabetes Mellitus8Pulmonary Hypertension4Coronary Artery Disease3Angina2Angina Pectoris2Heart Failure2Pulmonary Arterial Hypertension2Adenocarcinoma of the Prostate1Atrial Fibrillation1Bone Metastases1Diabetes Mellitus, Type 21Diabetes, Type I1Diabetes, Type II1Diastolic Heart Failure1Diastolic Left Ventricular Dysfunction1Heart Failure With Preserved Ejection Fraction1Ischemic Cardiomyopathy1Nonischemic Cardiomyopathy1Right Heart Failure1Right Ventricular Dysfunction1Silent Myocardial Ischemia1Soft Tissue Metastases1Stage IIA Prostate Cancer1Stage IIB Prostate Cancer1Stage III Prostate Cancer1
Mapped diseases appearing in these trials
Shared study participation does not establish that this intervention treats a disease.
Leading sponsors
Gilead Sciences
10
University of Pennsylvania
2
Boston University
1
Brigham and Women's Hospital
1
Intermountain Health Care, Inc.
1
Northwestern University
1
University of Alberta
1
University of California, San Diego
1
University of Chicago
1
University of Colorado, Denver
1
University of Rochester
1
Walter Reed National Military Medical Center
1
Trial status mix
COMPLETED18
WITHDRAWN2
RECRUITING1
TERMINATED1
Phase mix
PHASE36
PHASE45
PHASE14
PHASE24
NA3
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.